about
Vitamin D supplementation and breast cancer prevention: a systematic review and meta-analysis of randomized clinical trialsAnticoagulation for people with cancer and central venous cathetersLow molecular weight heparin versus unfractionated heparin for perioperative thromboprophylaxis in patients with cancerAnticoagulation for the initial treatment of venous thromboembolism in patients with cancerOral anticoagulation in patients with cancer who have no therapeutic or prophylactic indication for anticoagulationAnticoagulation for the long-term treatment of venous thromboembolism in patients with cancerOral anticoagulation in patients with cancer who have no therapeutic or prophylactic indication for anticoagulationAnticoagulation for the initial treatment of venous thromboembolism in patients with cancerFraming of health information messagesLow molecular weight heparin versus unfractionated heparin for perioperative thromboprophylaxis in patients with cancerAnticoagulation for the initial treatment of venous thromboembolism in patients with cancerAnticoagulation for patients with cancer and central venous cathetersOral anticoagulation in patients with cancer who have no therapeutic or prophylactic indication for anticoagulationAnticoagulation for the initial treatment of venous thromboembolism in patients with cancerOral anticoagulation in patients with cancer who have no therapeutic or prophylactic indication for anticoagulationAnticoagulation for the long-term treatment of venous thromboembolism in patients with cancerAnticoagulation for patients with cancer and central venous cathetersAnticoagulation for the initial treatment of venous thromboembolism in patients with cancerAnticoagulation for the long term treatment of venous thromboembolism in patients with cancerAnticoagulation for thrombosis prophylaxis in cancer patients with central venous cathetersOral anticoagulation for prolonging survival in patients with cancer
P50
Q21089763-4BABFBA4-D02F-41C8-A9A4-3BC55DE5EEE5Q24193103-7A2895EC-8D64-450F-8A4C-8DB1AD390624Q24193749-3D572D7D-8A52-4D59-BCAB-FC6BB0B0DCA8Q24193871-890BF0D8-D42C-4E6E-84BB-31DCF7731048Q24194116-DF37D8F0-14AC-410E-9E78-1B3AB03580FCQ24194904-4C904B9C-EF5D-4B9A-A103-64ADDFF327C8Q24194926-BF1D8126-4CA4-4320-83D0-63A9A114DC0AQ24234155-CE5B2C39-0BBF-47A2-B92F-6E4660A9B706Q24234467-8DAD9A71-9BAC-40ED-9390-92EDDE175A9EQ24235023-8CF280C6-8FBE-452F-8E6A-9174DFF46BFAQ24235193-2E00AA66-7A4A-46B1-9511-CB0AC579C14AQ24235260-D7BD8A83-2EC1-432A-B044-53CB5BC32367Q24235785-16CB304C-0CBF-4CFD-949F-46C00C36DB97Q24236443-C7FF616F-F1B0-4B85-88A4-750CA8167DFFQ24236595-EE738891-5C63-41A7-85F9-4DE74E3E2F0BQ24236620-9FD66E2C-9C2E-476D-A153-3B578B556CD7Q24236648-238767B6-04BD-4108-A625-223D4AD2E571Q24242243-E4E4122F-FC26-4160-B53E-8227B1611437Q24243286-D2EB0003-0EF5-4E8A-8E5A-E631B53BE6F2Q24244042-26815220-5081-472F-B47B-039F76A9C05CQ24245072-B1508836-3C0C-4F98-B7D3-81D25BF3784A
P50
description
hulumtuese
@sq
onderzoeker
@nl
researcher
@en
հետազոտող
@hy
name
Francesca Sperati
@ast
Francesca Sperati
@en
Francesca Sperati
@es
Francesca Sperati
@sl
type
label
Francesca Sperati
@ast
Francesca Sperati
@en
Francesca Sperati
@es
Francesca Sperati
@sl
prefLabel
Francesca Sperati
@ast
Francesca Sperati
@en
Francesca Sperati
@es
Francesca Sperati
@sl